Targets › CES1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology.
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. (UniProt, P23141)
Open in Phaseline: the race on CES1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | Carboxylesterase-expressing Allogeneic Neural Stem Cells Genetically modified neural stem cells expressing carboxylesterase (CE) to enhance tumor s | CES1 | Phase 1 | Recurrent Anaplastic Astrocytoma | – |
Recurrent Anaplastic Astrocytoma (1)
mixed (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.